

Online Table 1. Bleeding localisation

	6-week group (n=114)	6-month group (n=122)
Intracranial	2 (1.8)	2 (1.6)
Gastrointestinal	23 (20.2)	27 (22.1)
Urogenital	4 (3.5)	4 (3.3)
Access Site	14 (12.3)	14 (11.5)
Epistaxis	29 (25.4)	39 (32.0)
Skin	30 (26.3)	29 (23.8)
Other	12 (10.5)	7 (5.7)


Values are n(%). No significant differences were observed.

Online Table 2: Landmark analysis from 6 weeks to 6 months

	Landmark Analysis 6 weeks to 6 months			
	6-week group	6-month group	Hazard ratio (95% CI)	p value
Primary endpoint				
Death, myocardial infarction, stent thrombosis, stroke or major bleeding	6 (2.1)	14 (4.7)	0.44 (0.17 - 1.12)	0.09
Secondary endpoints				
Cardiac death, myocardial infarction stent thrombosis or ischemic stroke	2 (0.7)	6 (2.0)	0.34 (0.07 - 1.56)	0.19
TIMI major bleeding	3 (1.0)	7 (2.4)	0.43 (0.12 - 1.62)	0.23
Death	3 (1.0)	7 (2.3)	0.43 (0.12 - 1.60)	0.22
Cardiac death	2 (0.7)	4 (1.3)	0.50 (0.09 - 2.65)	0.43
Myocardial infarction	0	0	-	-
Definite stent thrombosis	0	0	-	-
Stroke	0	2 (0.7)	-	> 0.99
Ischemic stroke	0	2 (0.7)	-	> 0.99
TIMI major and minor bleeding	9 (3.2)	13 (4.5)	0.71 (0.30 - 1.65)	0.43
TIMI major bleeding	3 (1.0)	7 (2.4)	0.43 (0.12 - 1.62)	0.23
TIMI minor bleeding	6 (2.1)	6 (2.1)	1.01 (0.33 - 3.14)	0.98
Any BARC bleeding	31 (13.1)	55 (21.8)	0.57 (0.37 - 0.88)	0.01
BARC 1	19 (7.1)	27 (9.7)	0.72 (0.40 - 1.29)	0.27
BARC 2	4 (1.4)	14 (4.9)	0.28 (0.10 - 0.79)	0.03
BARC 3a	4 (1.4)	6 (2.1)	0.67 (0.19 - 2.36)	0.54
BARC 3b	4 (1.4)	8 (2.7)	0.51 (0.16 - 1.65)	0.27
BARC 3c	0	0	-	-
BARC 4	0	0	-	-
BARC 5a	0	0	-	-
BARC 5b	0	0	-	-
BARC bleeding ≥ 2	12 (4.5)	28 (10.3)	0.43 (0.22 - 0.82)	0.01


Numbers are Kaplan Meier Estimates rather than percentages. TIMI= Thrombolysis in Myocardial Infarction criteria. BARC= Bleeding Academic Research Consortium criteria.

Online Figure 1: Trial flow of ISAR-TRIPLE



ISAR-TRIPLE (The *In*tracoronary *S*tenting and *A*ntithrombotic *R*egimen - *T*esting of a six-week versus a six-month clopidogrel treatment *R*egimen *I*n *P*atients with concomitant aspirin and ora*L* anticoagulant therapy following drug-*E*luting stenting trial), OAC (oral anticoagulation)

Online Figure 2: Subgroup analysis for the primary endpoint.



Nine month incidence and hazard ratio (HR) of the primary endpoint (cumulative incidence of death, myocardial infarction, stent thrombosis, stroke or Thrombolysis in Myocardial Infarction (TIMI) major bleeding) in prespecified subgroups.

ISAR TRIPLE study groups

Steering committee: A Kastrati, S Schulz-Schüpke, J Mehilli, K-L Laugwitz

Clinical event adjudication committee: G. Ndrepepa, MD, M. Linhardt, MD, P. Barthel, MD

Data safety monitoring board: J. Mann, MD, F. Hofmann, MD, K. Ulm, PhD

Patient follow-up and data coordination at the ISAResearch Centre: K A Fiedler, N Sarafoff, J Mehilli, R A Byrne, S Schulz-Schüpke, H Holle, K Hösl, F Maimer-Rodrigues, H Paul, N Rifatov, G Schömig, M Schulz, B Wolff, B von Merzljak, I Zenullahi, U Sonntag, L Neumann, J Wealer, S Floh

Patient follow-up and data coordination at Aarhus University Hospital: M Maeng, L Jørgensen